Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K, Izquierdo MM, Cadenas FL, Ramos F, Sánchez JMH, Lumbreras E, Robledo C, Del Real JS, Caballero JC, Collado R, Bernal T, Pedro C, Insunza A, de Paz R, Xicoy B, Salido E, García JS, Mínguez SS, García CM, Muñoz AMS, Barba MS, Rivas JMH, Abáigar M, Campelo MD.
Janusz K, et al. Among authors: salido e.
Ann Hematol. 2021 Aug;100(8):1995-2004. doi: 10.1007/s00277-020-04360-4. Epub 2021 Jan 6.
Ann Hematol. 2021.
PMID: 33409621